Clinical trial
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With…
NCT00060372 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00060372 |
|---|---|
| Title | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
| Official title | CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8, 21)(q22 and 59 more |
| Intervention type | Drug |
| Interventions | ipilimumab, therapeutic allogeneic lymphocytes |
| Enrollment | 21 |
| Start date | Apr 1, 2003 |
| Primary completion | Apr 1, 2008 |
| First posted | May 7, 2003 |
| Last update posted | Mar 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: